...in a NASDAQ IPO after withdrawing its planned listing in July.On the flipside, immuno-oncology company Compass...

...on Medical Product Access, Safety and Stewardship (COMPASS). Steve...

...Friday’s session, neurodegeneration play Athira gave back most of its early gains, while depression company Compass...
...in a series B round announced in June (see “Recovering Neuronal Health”).Demand was high for Compass...
...$14-$16.During Friday’s session, Compass gained $12 (71%) to $29, lifting its market cap above $1 billion.Compass’...

...ATH-1017 in Alzheimer’s disease patients (see “Athira Seeks to Recover Neuronal Health”).Compass seeking U.S. debutU.K.-based Compass...
...high-purity polymorphic crystalline formulation of psilocybin, for treatment-resistant depression. BC Staff Synthego Corp. Clene Nanomedicine Inc. Antengene Corp. Athira Pharma Inc. Compass...

...shares fell $3.61 (11%) to $30.73 Wednesday. After merger, Compass raises $60M Antibody therapeutics company Compass...
...raises $60M Antibody therapeutics company Compass completed a reverse merger with Olivia Ventures Inc., becoming Compass...
...S. Eaton, Staff Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass...

...Bridge Venture Partners and Polaris Venture Partners. Compass completes $80M B round Mental health company Compass...
...Camden Partners Nexus, Perceptive Advisors, Skyviews Life Science and Soleus Capital. The financing will enable Compass...

...all of the bispecifics discussed are designed to bind T cells. A preclinical study from Compass...
...others each bind two coagulation factors to treat hemophilia. The others include an antibody from Compass...